Defence Therapeutics Inc (TSE:DTC) has released an update.
Defence Therapeutics Inc. has secured a significant U.S. patent for its AccuTOX technology, which provides a novel method for inducing cancer cell death and paves the way for a new class of antibody-drug conjugates. The technology holds promise for the treatment of multiple cancer types and has received FDA approval to enter Phase I clinical trials for melanoma. The patent grants the company market exclusivity until 2042, enhancing its commercial prospects and investor appeal.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.
